Key Takeaways Stem cells for psoriasis remain experimental, and the human evidence comes from very small studies. Cochrane’s living review found that biologic medicines cleared skin better than older tablets across 204 studies. A 2022 trial of 17 people found 8 had at least 40% skin improvement after cord cell
Key Takeaways Stem cell therapy for cerebral palsy is still experimental and is not established standard care. A 2021 randomized trial of 72 children reported higher motor scores 12 months after cord tissue cells than after a pretend procedure. Two 2025 reviews found average gains of about 1 to 1.5
Key Takeaways Stem cell therapies for kidney disease are still experimental, and a 2025 review found lower inflammation markers in animals but no clear change in people. That review pooled 49 animal studies and only three small human trials involving 86 people. Standard care, such as blood pressure control, remains
Key Takeaways Researchers test stem cell therapies for heart failure, but no trial shows that the cells rebuild a damaged heart. A 2016 Cochrane review of 38 trials and 1,907 people found no gain in heart pumping strength and rated the evidence low quality. A 2012 trial of 30 people
Key Takeaways Mesenchymal stem cells (MSCs) have been tested in small rheumatoid arthritis (RA) trials, but no trial shows they stop the disease for good. A 2019 study of 64 people with RA reported lower disease scores at one and three years after umbilical cord cell infusion. A 2017 placebo-controlled
Key Takeaways Mesenchymal stem cell (MSC) therapy has been tested in small human trials for chronic lung inflammation, but none show it reverses lung scarring. A 2013 randomized trial of 62 people with chronic obstructive pulmonary disease (COPD) found no lung function gain from infused MSCs. A 2020 randomized trial
